DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Defense Health Agency Contracting Activity - DHACA · Military Medical Research and Development (12.420)
Posted 4 May 2026 · Closes today
In plain terms
The US Defense Health Agency funds high-risk, innovative research on amyotrophic lateral sclerosis therapies and drug discovery through awards to any type of organization, with applications due by 30 September 2026. This deadline has now passed and the call is no longer accepting applications.
A generated summary of the donor's text; the original wording is below.
Summary
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.
Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.
Excerpt from the donor's page. The full text, annexes and forms are on the original call.
Who can apply
- ngo_cso
- community_based_org
- government
- academia_research
- private_company
- social_enterprise
- individual
- un_agency
- other
Eligibility and conditions
Show the eligibility text from the source
Applicant types: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"